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1. Introduction 
1.1. Medulloblastoma 
Medulloblastoma (MB) is the most common malignant pediatric brain tumor. It 
represents about 15–20% of the central nervous system (CNS) malignancies, 40% of 
which are located in the posterior fossa.(1) Despite the evidence that survival rates 
have increased by 30% in the past 20 years, today many patients still have a poor 
prognosis. (2) MB are embryonic CNS tumors constituted by primitive-appearing cells 
that can differentiate along multiple lineages. It arise from cerebellum and it is not 
completely understood which specific cells subset gives rise to these malignancies. 
One common theory is that MB starts from mutations in proliferating granule neuron 
precursors (GNPs) in the external germinal/granular layer (EGL). (3) The histological 
disease features reveal a heterogeneous disorder, in fact four variants of MB have 
been identified: classic, desmoplastic/nodular (D/N), extensive nodularity (MBEN), 
anaplastic and large cell, the latter often coexisting in the large cell/anaplastic (LC/A) 
variant. (4,5) MB is not a single disease, but a heterogeneous mixture of various 
subgroups with distinct features. The genomic profiles show four distinct molecular 
subgroups that have been identified: Wingless (WNT), Sonic Hedgehog (SHH), 
Group 3 and Group 4. (6,7)(Figure 1) Each subgroup corresponds to specific survival 
rate, age demographics, and genetic aberrations.(8) WNT and SHH subgroups are 
named after the discovery of the signaling pathway that plays a prominent role in the 
pathogenesis. (9) Molecular subgroups are correlated to clinical outcome. For this 
reason, they were integrated in the most recent version of WHO classification of CNS 
malignancies (5) and applied into the clinical practice. These MB subgroups remain 
stable at recurrence and are likely remindful of original cells. Recent research on 763 
MB samples by Cavalli and colleagues (10) has shown the presence of inter-tumoral 
heterogeneity within the four MB subgroups delineating the presence of 12 subtypes 
based on gene expression and DNA methylation features, but the degree of 
heterogeneity and the extent of overlap are still unknown. This newfound 
heterogeneity within subgroups could explain previously unknown variation.(10) 
Thus, much emphasis has been recently placed on further identifying new alterations 
that may occur in each subtype pathway. Moreover, Northcott et al. described the 
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whole genome landscape of MB subtypes analysing 491 patient tumours.(11) They 
showed that driver mutations could be assigned to the two most malignant forms, 
group 3 and group 4 MB. In particular, in-frame insertions hotspot that target 
KBTBD4 (Kelch Repeat And BTB Domain Containing 4) and activation of PR/SET 
Domain 6 (PRDM6) were identified.(11) These and other novel findings identified in 
the MB subgroups could lead to the discovery of attractive targets for MB, which 
have not previously been explored in detail. 
 
1.2. Molecular characterization of MB subgroups 
WNT is the less common molecular MB subgroup and accounts for about 10– 11% of 
all MB. (12) It shows the main incidence at 10–12 years of age, being very rare in 
infants, with no differences in gender predilection. The typical histology is most 
frequently encountered, with rare cases of the LC/A variant and metastatic 
dissemination. (13) The main characteristic in WNT tumors is the somatic activating 
mutations in exon 3 of β-catenin (CTNNB1), shown in 85% of WNT MB with a 
predictive good outcome for patients. (14) However, the link between a better 
prognosis due to biological effect of Wnt/β-catenin signaling activation have not been 
fully clarified yet. (15) Monosomy 6 is the primary recurrent structural chromosomic 
alteration, present in the 80–85% of cases. Other common mutations are in DDX3X 
gene and the missense mutations in TP53 (15% of cases), that is a marker of high 
risk in the SHH subgroup but with no evidence in differences in the WNT patients 
survival rate. (16) 
The SHH subgroup that represents 28–30% of all MB, has a bimodal age distribution, 
being more frequent in infants and adults, with a weak male predominance among 
infants. (17) The prognosis depends on the associated mutation meaning that these 
patients have an intermediate prognosis, with 5-years survival ranging between 60% 
and 80%, but the mutations in MYCN or TP53 oncogenes worsen the prognosis. (18) 
D/N and MBEN histology are the main features associated with the SHH subtype, 
however, it is also possible to observe classic or LC/A histology. (13) There are 
typical genetic alterations that lead to the SHH signaling over-activation: the most 
common ones are the somatic or germ-line inactivating alterations or the loss of 
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PTCH1 and SUFU, or the somatic missense mutations activating SMO. (19,20) Few 
SHH patients showed high-risk disease due to co-amplification of MYCN and GLI2, 
accompanied by inactivation of TP53. (16) Patients with Gorlin syndrome, carriers of 
a germ-line mutation on PTCH1, have a predisposition to develop basal-cell 
carcinoma and MB, especially MBEN. (21) Unusual SHH subgroup MBs has also 
been reported in patients with rare diseases such as Fanconi anemia. (22) 
The Group 3 has around 25-28% incidence of all MB and these patients exhibit the 
worst survival rate and the highest rate of metastatic dissemination. (23) Group 3 
MBs are very rare in adults but are common in infants and younger children, with a 
male to female ratio of 2:1. (13) LC/A is the principal histology and the tumor genome 
is considerably unbalanced. Several numbers of broad alterations were find such as 
gain of chromosome 7 and iso-chromosome 17q. There are also associations with 
neurocutaneous syndromes such as tuberous sclerosis complex that have been 
described. (24) 
Group 4 MBs share many of these alterations.(25) The most common event is the 
MYC amplification (10– 20%), followed by OTX2 transcription factor mutations, which 
affect the 10% of patients and is mutually exclusive of MYC amplification. The 
incidence of Group 4 is about 34–35% of all MBs, and it is the most common 
subgroup. (12)This subgroup is rare in infants, it exhibit a peak incidence in 10-years-
old children, with a prevalence in males (sex ratio 3:1). They can have classic or 
LC/A histology. Group 4 MBs have an intermediate prognosis and show a high rate 
of metastasis and relapse. MYCN amplification is not associated with the worst 
outcome such as the SHH subgroup. (26) 
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Figure 1 
 
 
Figure 1. Molecular subgroups of medulloblastoma. WNT: wingless, SHH: sonic 
hedgehog, M : male, F : female. (27) 
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1.3. MB therapeutic approaches 
Nowadays the treatment for MB is based on surgery followed by craniospinal 
chemotherapy and irradiation. However, CNS radiation therapy can be harmful to the 
developing brain and is usually spared in children under the age of three, but this can 
affect the disease control and survival. Moreover, the post-surgery treatment with 
chemotherapy and irradiation are fundamental to eliminate any residual tumor cells 
leading to the reduction of metastases risk occurrence. However, it is relevant to 
consider that the same treatments leading to increased survival rates are also 
causing potentially debilitating physical deficits, such as endocrine dysfunction, 
neuropsychological deficits or subsequent malignancies. Indeed, the outcomes in 51 
long-term survivors of paediatric MB were comprehensively assessed in terms of 
tumour control, neurological, endocrine, and neurocognitive complications and their 
impact on behavioural and psychological adjustment, and health-related quality of life 
(QoL). (28) Endocrine deficits occurred in 61%, neurological complications in 72%, 
and significant school problems in 72%. All patients had significant deficits in 
neurocognitive functioning: attention and processing speed was impaired in 79%, 
learning and memory in 88%, language in 56%, visual perception in 50%, and 
executive functions in 64%. Because of their treatment, including craniospinal 
radiotherapy, MB long-time survivors are not only at great risk for neurological, 
endocrine, and neurocognitive complications, but also of social isolation thereby 
decreasing self-rated QoL substantially. 
Thus, there is a need for the development of new strategies that may significantly 
ameliorate outcome and QoL especially in the younger population and decrease 
potential side effects. MB tumors possess peculiar features different from peripheral 
tumors, and many factors such as the blood brain barrier (BBB) and the hostile tumor 
microenvironment should be considered. The disease understanding is critical, in fact 
one of the major obstacles is the drug delivery due to the MB brain localization. The 
tumor cells usually grow in the cerebellum midline. The patients present increased 
intracranial pressure (ICP) and typical signs of obstructive hydrocephalus. The 
symptoms usually are headaches and nausea/vomiting for weeks to months prior to 
disease discovery. Irritability and poor feeding could also affect young children, with 
severe cases that show altered mental status. Other physical signs found during 
patients’ examination are bradycardia, hypertension and widened pulse pressure. 
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With a severe hydrocephalous degree we can have ocular findings such as 
papilledema and 6th nerve palsies.(29) The perfect scenery for MB patients is the 
maximal tumor resection and the first step is the surgery. Approximately 25% of MB 
patients develop the posterior fossa syndrome after surgery, leading to some degree 
of cerebellar mutism where patients try to produce words but are unable and start to 
be extremely irritable, and provoke hypotonia and ataxia. The syndrome is usually 
exhibited 24 hours after resection of a posterior fossa tumor and the duration is 
variable from weeks to months, but the language difficulties may be lifelong.(30) 
Other complications of surgery include disruption of the blood supply leading to 
infarction of surrounding normal brain, and intra-operative bleeding leading to 
subdural hematomas. 30 days after definitive surgery the patients is recruited for the 
radiation therapy (XRT).(31,32) Daily fractions of 1.8 Gy to a final dose of 54 Gy - 
59.4 Gy are used. There is high risk to develop complications due to XRT for 
pediatric patients with MB. Radiation therapy could lead to anorexia and nausea due 
to the proximity of the spinal fields to the gastro intestinal tract. It is fundamental to 
control the patient’s weight and nutrition during the treatment. The bone marrow of 
the vertebral bodies is active and important for the maintenance of normal blood 
counts, so cytopenias often appear during this period. Most MB patients require XRT 
for long term survival, and treatment costs are very expensive.  
Moreover, another approach is the pharmacological treatment. It is based on 
chemotherapy drugs administration and the aim is to enhance the local control of 
tumor and the management of micrometastatic disease. The drugs’ mechanism 
affects rapidly dividing cells and also damages the gastro intestinal tract, hair 
follicles, and bone marrow. This leads to risk of nausea and vomiting, diarrhea and/or 
constipation, hair loss and myelosuppression. The chemotherapy is used specifically 
depending on the MB patient characteristic and there are protocols to well establish 
the correct treatment. Some examples of used drugs are: Cisplatin, mechanism of 
action: induces cellular apoptosis by cross-linking DNA;(33) Cyclophosphamide, 
mechanism of action: alkylating agent; Lomustine, mechanism of action: alkylating 
agent; Vincristine, mechanism of action: microtubule inhibitor that prevents cell 
division by binding to the tubulin component of microtubules and leading to 
metaphase arrest.(34) 
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1.4. Immunotherapy for MB 
Cancer immunotherapy is a new advanced medicine approach that allows triggering 
the cytotoxic potential of the immune system against cancer cells. In particular, T 
cells adoptive immunotherapy is one of the best-characterized and used strategies 
nowadays, with several clinical trials opened worldwide. T cells are the cells 
responsible to fight foreign pathogens that pretend to be ‘self’. T cells are able to 
recognize mutated or infected cells through antigens (small peptides) presented by 
the major histocompatibility complex (MHC) class. (35)Tumor cells evolve through 
mutations from the phenotype of their origin cells and de-differentiate and up-regulate 
the expression of proteins normally not exhibited by the origin cells, the tumor 
associated antigens (TAA). Cancer immunotherapy is based on the possibility of T 
cells (or other immune system component) to recognize TAA. Unlike traditional 
pharmacologic agents that require increased titration for full effect (often with dose 
limiting toxicities that preclude rampant dose escalation), immunotherapy is a biologic 
agent that may not necessitate the same dose-dependent increases for maximal 
impact. (36) For instance, the law of the impassable BBB is now changing opening 
new scenery for the in “vivo biology” respect the difficulties of the bio-distribution of 
pharmacological treatment. Recently, lymphatic drainage networks have been 
described within the CNS that communicate with deep cervical draining lymph nodes. 
(37-41) Activated T cells able to recognize tumor-specific antigens are able to 
traverse the BBB through adhesion markers (i.e., VLA-4), allowing them to penetrate 
the tumor microenvironment and induce their effector functions against pediatric 
cancer cells. (37-41) 
For children with malignant brain tumors, immunotherapy may be used in conjunction 
with standard therapy but we should consider the impact of traditional protocols on 
the immunotherapy treatment. XRT may confound Th1 type responses by decreasing 
CD8+ dendritic cells (42,43) but can damage the tumor environment with the release 
of damage associated molecular patterns (DAMPs) and tumor antigens that can be 
processed by endogenous antigen presenting cells (APCs) for presentation to T cells 
in local draining lymph nodes. (44)Instead, chemotherapy can be directly toxic to 
activated T cells, but may eliminate regulatory populations (i.e., regulatory T cells, 
myeloid derived suppressor cells) that compete for essential cytokines.(45-47) The 
adoptive cellular therapy is best utilized after radiation and chemotherapy; moreover, 
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all these treatment modalities may synergize also with a vaccine immunotherapy. 
(48,49) Preclinical and clinical investigations have shown that vaccination through 
repeated cycles of chemotherapy enhances antigen specific T cell immunity.(49–51) 
We can image to use an adoptive cellular therapy followed after by chemotherapy 
with continued vaccination cycles to maintain immunologic memory.  
Focusing our attention on pediatric brain tumors, appropriate tumor antigens have to 
be selected and targeted, avoiding immunologic targeting of epitopes expressed on 
normal tissue that may elicit autoimmunity. (52) Most pediatric brain tumors have low 
mutational rate at the genomic level but are prompted by epigenetic deregulatory 
mechanisms that lead to the re-expression of developmental fetal antigens in 
malignancies, such as MB and primitive neural ectodermal tumors (PNETs). (53-55) 
The immune system actively survey against cancer and is able to recognize and 
remove cells that are undergoing oncologic transformation.(56,57)The immune 
system triggers a response when a critical mass of cancer cells develops, but 
consequently, tumor cells evolve to escape the immune surveillance and re-populate 
the mass.(56,57) (Figure2) This new tumor microenvironment becomes comprised of 
immunoregulatory populations, including FoxP3+ regulatory T cells, tumor associated 
macrophages, and myeloid derived suppressor cells, which actively suppress the 
cytotoxic effect modulating effector T cells.(58–60) Immunotherapy can be employed 
to help the cytotoxic components to escape the hostile tumor environment in order to 
develop a novel effective tumor response.  
Immune checkpoint blockade antagonizes inhibitory receptor/ligand interactions (i.e., 
programmed death-ligand 1 (PD-L1) on APCs and tumor cells/programmed death-1 
(PD-1) receptor on T cells) designed to inhibit activated T cells.(61)Today with 
monoclonal antibodies (mAbs) we are able to block these inhibitory axes in order to 
re-activate T cells and  to elicit their anti-tumor effector functions.(61) Checkpoint 
inhibitors have been shown remarkable results against adult cancers (i.e., skin and 
lung), but pediatric malignancies are distinct.(62) Moreover, immune checkpoint 
mAbs are not expected to cross the BBB; however, in the presence of tumor, 
chemotherapy and radiation, this barrier may be perturbed, allowing these molecules 
to translocate. (63,64) Clinical trials are currently underway in children with high 
grade gliomas (HGGs) and DIPGs (phase I, clinicaltrials.gov: NCT02359565) to 
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determine the utility of these agents against pediatric CNS malignancies.  
Since childhood brain cancer is a developmental topic, the generation of novel 
immunotherapy strategies is necessary. While checkpoint inhibitors (i.e., PD-1 and 
PD-L1 mAbs) are promising candidates that can be leveraged for all patients, they 
appear to require tumors with high mutational burdens and PD-1+ intratumoral T cells 
(or high expressing PD-L1+ tumors).(61,62) CD47 is an immune evasion marker on 
the surface of many solid cancers that could be used as a tumor immunosuppressive 
target. (65) CD47 is overexpressed by malignant cells to evade the innate immune 
response and may be particularly enriched in pediatric brain tumors including MB, 
acute teratoid rhabdoid tumor, pediatric glioblastoma, and DIPG.(65) Pre-clinical 
studies with a humanized mAbs antagonizing CD47 have demonstrated that 
macrophages can be unlocked to phagocytize tumor cells in several pediatric brain 
tumor models. (65) In addition to CD47 targeting, tumor immunosuppression can be 
overcome through targeting indoleamine 2,3-dioxygenase (IDO).(66,67) IDO is an 
enzyme used by effector T cells to deplete tryptophan (critical for cells survival and 
longevity), an essential amino acid, and this protein is overexpressed in malignant 
brain tumors. (66,67) Tumors that utilize IDO deplete tryptophan from T cells forming 
kynurenines, which predispose an exhausted and regulatory T cell phenotype.(66,67) 
IDO blockers have been developed and are currently evaluated in children in early 
phase studies (phase I, clinical trials.gov: NCT02502708). (68) 
Alternatively, other strategies discussed above have been employed to activate 
immunologic responses de novo against pediatric brain tumors, like cancer vaccines. 
The treatment consist to deliver tumor antigens to APCs allowing them to process 
and present these epitopes on the surface of their MHC class I and II molecules for 
presentation to T cells. (69) Glioma associated peptide vaccines with poly-I/C have 
been investigated in HLA-A*002 positive patients with DIPG and HGGs. (70) These 
peptides (commonly expressed in childhood gliomas) included EphA2, interleukin-13 
receptor alpha, and survivin. (70) Thirteen of twenty-one children treated with these 
peptide vaccines had an immune response to the antigens. (70)These results are 
promising but HLA-A*002 restricted constraining eligibility to patients that express 
this haplotype. Alternatively, DNA or RNA based vaccines bypass HLA haplotype 
restriction, allowing an individual’s cell machinery to transcribe/translate nucleic acids 
into proteins for personalized processing. (71-74) 
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Like vaccines, oncolytic viral therapy intends to induce endogenous immune 
responses. (75-79) Oncolytic viruses are attenuated or genetically modified in order 
to preferentially propagate in tumor cells to allow the recognition of oncologic cells by 
the immune system for rejection. (75-79) Oncolytic viral therapy has been employed 
in several cancers with promising results and is currently being evaluated in phase I 
studies in children with recurrent supratentorial tumors (using herpes simplex virus; 
clinicaltrials.gov: NCT02457845). (80) 
Nowadays, the best developing approach is the engineered chimeric antigen 
receptor (CAR) modified T cells, which can be utilized to target surface antigens. (81-
86) Recently, in the field of CNS tumors, CAR T cells have been shown to mediate 
significant anti-tumor activity against adult glioblastoma by targeting HER2 or 
IL13Ra2, which can be employed against pediatric high-grade gliomas (phase I, 
clinicaltrials.gov: NCT02208362). (87,88) CAR T cells have the binding antibody 
capacity with the cytotoxicity of a T cell, with the possibility off-target side effects. (81-
86)The targeting of normal antigens by CAR T cells in the brain may lead to CNS 
inflammation, neurotoxicity, and risks for an increased intracranial pressure and 
herniation. Future development of CAR T cell therapies that activate only after 
binding to multiple tumor surface antigens may limit these off-target effects. 
(89)Instead, we can genetically modified T cells in order to express an exogenous 
TCR with the same CAR based immunosuppressive cancer effect. Exogenous TCR 
are able to recognize antigens presented by MHC class I or II, thus implicating 
haplotypes restriction. 
Other types of adoptive cell therapies for pediatric brain tumors include the 
transplantation of autologous/allogeneic tumor-specific cytotoxic T lymphocytes and 
natural killer (NK) cells. In children with posterior fossa tumors, autologous NK cells 
are being be expanded ex vivo before forth ventricular infusion (via ommaya 
reservoir) (phase I, clinicaltrials.gov: NCT02271711). Allogeneic T and NK cells are 
also being administered after non-myeloablative haploidentical transplant (reduced 
intensity conditioning regimens) to enable graft versus tumor killing against high risk 
solid tumors (i.e., pediatric brain tumors) (phase II, clinicaltrials.gov: NCT01804634 
and NCT02100891).  
Synergistically approach joined with novel strategies development is the best way to 
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speed up the fight against pediatric brain tumors. These early phase studies are 
important to better understand the optimal dose, safety, and efficacy of these 
investigational agents. While aggressive surgical resection, radiation, and 
chemotherapy have improved the cure rates for many pediatric patients with 
malignant brain tumors, the important side effect lead to a poor patients QoL, and  
these cancers remain the most common cause of solid cancer death in children. (90) 
New targeted therapies are vital to improve treatment outcomes, but must be 
developed to enable trafficking across the BBB.  
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Figure 2 
 
Figure 2. Cancer immunoediting paradigm. It defines the dynamic relationship between 
tumor development and anti-tumor immunity. (92) 
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1.5.A New Target for MB Immunotherapy: PRAME 
Cancer cells must be recognized from their surrounding environment to allow 
adoptive T cell immune mediated tumor toxicity. Nowadays, a well-established 
characterization of TAAs is critical for the correct development of new strategies in 
order to obtain a potential tumor-specific antigenic repertoire. Due to brain 
complexities, it is fundamental to discard immunological off-targets. In MB contest, 
among the potential tumor antigens, some of the best typified are the so-called 
cancer testis antigens (CTAs).(93,94) CTAs (the most common are MAGE and 
GAGE proteins) were initially described in melanoma, where they were able to trigger 
an autologous T-cell-mediated anti-tumor response. CTAs are proteins normally 
expressed in normal male germ cells but over-expressed in several types of cancer 
cells and not in usual somatic cells, (95) CTAs are considered efficient biomarkers to 
target cancer cells due to their expression pattern and to develop immunotherapy 
strategies. (96,97) CTAs constituted an enormous genes’ family of closely associated 
members and are classified into two groups: the CT-X antigens that are encoded by 
the X chromosome and the non-X CTAs that are encoded by the autosomes. To 
date, 228 CTAs have been discovered: 120 CTAs (52%) map to the X chromosome, 
while all the others are present on the autosomes and Y chromosome. (98,99) 
Starting from melanoma, these antigens were also found being over-expressed in 
different cancer types like breast cancer, lung cancer, esophageal cancer, 
hepatocellular carcinoma, Acute Lymphoblastic Leukemia, and MB and their 
expression correlates with aggressive tumor phenotype and resistance to 
chemotherapy. (93) MB treated with current therapies exhibits compliances due to 
the severity of the treatment itself and is an ideal target for immunotherapy 
development. In the previous paragraph, we showed the feasibility of this strategies 
in the context of brain tumors, where immunotherapies are already been applied but 
improvement are necessary. These “biological technologies” has the potentiality to 
improve the current outcome in MB high risk patients. It is more effective in killing 
tumor cells and less toxic for the brain development than the current treatments. 
Recently, Amir Al et al, discovered a new HLA-A*002 restricted TCR able to 
recognize the preferentially expressed antigen in melanoma (PRAME) with high 
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affinity. (100) They showed the great capacity of this selected TCR to recognize and 
trigger an immune response against cells expressing PRAME. PRAME belongs to 
the cancer-testis antigens (CTA) family, and its expression has been demonstrated in 
several tumors (including melanoma, non-small cell lung carcinoma, breast 
carcinoma, renal cell carcinoma, head and neck cancer, Wilms' tumor and Hodgkin's 
lymphoma) and in germ-line tissues, whereas it has limited expression in healthy 
adult tissues. (101) 
PRAME may be explored for its feasibility of adoptive T cells immunotherapy for 
treatment of patients with MB, studying its up-regulation in this malignancy.  
PRAME was originally identified as a gene coding for HLA-A*024-presented 
antigens, able to stimulate tumor-specific cytotoxic lymphocytes (CTL) derived from 
melanoma patients. (102) PRAME is a protein of 509 amino acids with uncertain 
function that is encoded by the PRAME gene located on chromosome 22 
(22q11.22).(102) Few quantities of PRAME transcripts were displayed by 
trophoblasts and testis, normal adrenal, ovarian and endometrial cells. It is 
demonstrated that a clinically relevant characteristic of PRAME protein is an 
immunogenic nonapeptide able to induce a cytotoxic activity by T cells when 
presented by HLA-A24, thus, inspiring a potential role of PRAME as a target for 
immunotherapy.(102) Recently, a study of the PRAME physiologic role demonstrates 
that overexpression of this protein confers growth or survival advantages by 
antagonizing Retinoic Acid Receptor (RAR) signaling (103), and is causally involved 
in tumorigenic process. These features make PRAME a suitable target antigen for 
tumor immunotherapy. (104,105) Despite the possibility of in vitro reactivation of T 
cells progenitors specifically directed against PRAME peptides able to target 
leukemia HLA- matched cells (106-108), this approach remains difficult to translate 
into clinical application, for several reasons, including the scarce availability of 
“clinical grade” reagents, (produced with good laboratory procedures in compliance 
with “Good Manufacturing Practices”(GMP));the need to generate autologous 
antigen-presenting cells, as well as, the prolonged in vitro culture needed to generate 
clinically meaningful numbers of specific T cells.  
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2. AIMS OF WORK 
 
We chose to focus our project on PRAME as a target for an immunotherapy 
approach in patients with MB. 
To this end, the following aims were pursued:  
• Evaluation of PRAME expression in MB subgroups and its correlation with 
survival rate and patients outcome. 
• Cloning of a HLA-A*002+-restricted αβTCR specific for SLLQHLIGL PRAME-
derived peptide (SLL-TCR) to target HLA-A*002+ MB tumor cell lines.  
• Evaluation of in vitro functionality of SLL-TCR T cells against HLA-A*002+ MB 
tumor cell lines. 
• Development of a xenograft orthotopic mice model to assess the in vivo anti-
tumor activity of SLL-TCR T cells towards MB tumor. 
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3. Materials and Methods 
 
3.1. Cell lines 
The following cell lines: DAOY (desmoplastic cerebellar medulloblastoma, HLA-
A*02+), D283 Med (medulloblastoma, down-regulated HLA-A*02), CEMT2 (hybrids 
of human T and B lymphoblastoid cell lines, HLA-A*02+), RS4:11 (acute 
lymphoblastic leukemia, HLA-A*02-), U266 (myeloma, HLA-A*02+), HDML2 (Hodgkin 
lymphoma, HLA-A*02-) and HEK 293T/17 (Embryonic Human Kidney used to 
produce retroviral supernatant), were obtained from the American Type Culture 
Collection Company (ATCC). RS4:11, U266, HDML2 and CEM-T2 were maintained 
in culture with RPMI 1640 medium (EuroClone, Italy). DAOY and D283 MB cells were 
cultured in IMDM medium (EuroClone, Italy), while HEK 293T/17 in DMEM medium 
(EuroClone, Italy). Mediums contain 10% heat-inactivated, fetal bovine serum 
(EuroClone, Italy), 2 mM L-glutamine (GIBCO, USA), 25 IU/mL of penicillin, and 25 
mg/mL of streptomycin (EuroClone, Italy). Cells were maintained in humidified 
atmosphere containing 5% CO2 at 37°C. Identity of all cell lines was confirmed by an 
external lab (BMR Genomics srl) through PCR-single-locus-technology (Promega, 
PowerPlex 21 PCR); mycoplasma test was performed every three months.  
 
 
3.2. Healthy Donor’s PBMCs, MB patients and controls  
Peripheral blood mononuclear cells (PBMC) were isolated from either peripheral 
blood (PB) or buffy coat obtained from 8 healthy donors after obtaining written 
informed consent, in accordance with rules set by the Institutional Review Board 
(IRB) of Bambino Gesù Children’s Hospital of Rome (OPBG) (Approval of Ethical 
Committee N°969/2015 prot. N° 669LB), using Lymphocyte Separation Medium 
(Eurobio; France). MB specimens were obtained from a cohort of 60 patients with 
histologically-confirmed diagnosis who had undergone surgical resection at the 
OPBG between August 2011 and April 2015. All specimens were formalin-fixed, 
sectioned, stained with hematoxylin and eosin (H&E) and examined through 
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microscopy. In order to minimize inter-observer variability, histology was reviewed by 
an experienced neuropathologist, F.G., according to the international staging system 
for pediatric brain tumors. (109,110) The investigation was approved by the 
Institutional Review Board (Prot. N. 21LB; Study N 730/2013 OPBG). Informed 
consent was obtained from patient’s parents or legal guardians (as required per 
institutional review board policy). For all samples, around 0.5 cm3 of tumor’s tissue 
was also snap-frozen in liquid nitrogen and stored at -80°C until ready for RNA 
extraction. Clinical (age, gender and outcome), molecular and histopathological 
details of all 60 patients and of the 51 of them followed in our Institution are reported 
in Table 1. RNA of normal human cerebellum (10 adult samples from 25- to 70-year-
old subjects and 8 samples from 22 to 36-week-old foetuses) was purchased from 
Biocat (Heidelberg, Germany), Ambion (USA) and BD Biosciences (USA). MB 
primary cell lines were obtained from fresh patient’s tissue samples. In detail, tissues 
were collected in HBSS media (Thermo Fisher Scientific, USA) supplemented with 
0.5% glucose and 2% Penicillin/Streptomycin, grossly triturated with serological 
pipette and treated with DNAse-I (Sigma-Aldrich, United Kingdom) to a final 
concentration of 0.04% for 20 min. Finally, cells aggregates were mechanically 
dissociated using pipettes of decreasing bore size to obtain a single-cell suspension 
that was grown in DMEM/F12 medium + 10% FCS and 2% Penicillin/Streptomycin at 
5% CO2. After 1 week, the supernatant was removed from cultures and replaced 
with fresh medium. Two weeks after the start of the culture, cells were harvested and 
characterized for the expression of PRAME and neural markers (B3TUBB, S100A, 
GFAP) and re-plated to perform the experiments. In selected experiments, cell lines 
or primary MB patient-derived cells were pre-treated with 1,000 IU/mL of IFNγ (R&D 
System, USA) for 48 hours before their use as target cells. 
 
3.3. Retroviral constructs  
The complete PRAME specific αβTCR recognizing SLL-peptide in the context of 
HLA-A*02 (100) was cloned in a retroviral vector containing in frame the iC9 suicide 
gene sequence (iC9-SLL TCR). An additional retroviral vector encoding eGFP-
Firefly-Luciferase (eGFP- FFLuc) (111) was used in selected experiments to label 
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tumor cells (DAOY-FF-Luc.GFP and RS4:11- FF-Luc.GFP) for in vitro and in vivo 
studies, as previously described.(112)  
 
3.4. Generation and expansion of polyclonal iC9-SLL TCR T 
cells 
T lymphocytes were activated with immobilized OKT3 (1 µg/ml, e-Bioscience Inc., 
USA) and anti-CD28 (1 µg/ml, BD Biosciences, USA) antibodies in the presence of 
recombinant human interleukin-2 (IL-2, 100 U/ml; R&D, USA). Activated T cells were 
transduced on day 3 in 24-well plates pre-coated with recombinant human 
RetroNectin (Takara-Bio, USA), using a SFG retroviral supernatant specific for iC9-
SLL TCR. On day 5 from transduction, T cells were expanded in “complete medium” 
containing 45% RPMI1640 and 45% Click’s medium (Sigma-Aldrich, United 
Kingdom) supplemented with 10% FBS and 2 mMGlutamax, and fed twice a week 
with IL-2 (50U/ml). In selected experiments, iC9-SLL TCR T cells were generated 
from CD8+ or CD4+ T cells prepared by positive immunomagnetic sorting 
(MiltenyiBiotec, Germany), following the manufacturer's instructions. iC9-SLL TCR T 
cells were also sorted by anti- Allophycocyanin (APC) magnetic microbeads 
(MiltenyiBiotec, Germany), to select T cells previously stained with SLL-dextramers 
conjugated with APC (JPT, Germany).  
 
3.5. Activation of the suicide gene 
The chemical inducer of dimerization (CID) (AP1903; ARIAD Pharmaceuticals, USA) 
was kindly provided by Bellicum Pharmaceuticals (Houston, Texas, USA) and added 
at the indicated concentrations to either control T cells or iC9-SLL TCR T cells. The 
elimination of transgenic cells co-expressing the iC9 suicide gene was evaluated 24 
to 48 hours later by FACS analysis, enumerating the percentage of AnnexinV-/7-
AAD- Vβ1+ CD3+ T cells in the culture.  
 
 
19	
	
 
 
3.6. Immunophenotyping 
Expression of cell surface molecules was evaluated by flow-cytometry using standard 
methodology. The following monoclonal antibodies (mAbs) were used: SLL 
dextramer conjugated with APC (JPT, Germany); CD3 peridinin chlorophyll protein 
(PerCP)-conjugated monoclonal antibody; CD8 fluorescein isothiocyanate (FITC)-
conjugated monoclonal antibody; T- cell receptor-Vβ1 phycoerythrin (PE)-conjugated 
monoclonal antibody (all Ab were purchased from Becton Dickinson, USA). Control 
samples, labeled with an appropriate isotype-matched antibody, were included in 
each experiment. Samples were analyzed with a BD LSRFortessa X-20. Flow 
cytometry profiles were analyzed using the FACSDiva software (BD Biosciences). 
For each sample, we analyzed a minimum of 100,000 events.  
3.7. ELISpot assay 
We used an IFNγ ELISpot assay, as previously described. (66) Briefly, iC9-SLL TCR 
T cells were plated in triplicate, serially diluted from 1 × 105 to 1 × 104 cells/well, and 
then CEM-T2 (at the ratio 1:1) loaded with either the specific SLL peptides or ALY-
PRAME-derived irrelevant peptide were added at the indicated concentration (all 
peptides from JPT were dissolved in DMSO as indicated by the manufacturer). As a 
positive control, T cells were stimulated with 25 ng/mL of phorbolmyristate acetate 
(PMA) and 1 µg/mL of ionomycin (Sigma-Aldrich, United Kingdom). The IFNγ+ spot-
forming cells (SFCs) were enumerated (ZellNet, USA).  
3.8. Co-Culture assays 
For co-culture experiments, un-transduced control (CNT) and iC9-SLL TCR T cells 
were plated at 0.5x106 cells/well in 24-well plates at the indicated Effector:Target 
(E:T) ratios (1:1 and 5:1). Following 7 days of incubation at 37°C, adherent tumor 
cells and T cells were collected, and both residual tumor cells and T cells assessed 
by FACS analysis based on CD3 expression (Effector T cells) and GFP [(DAOY-FF-
Luc.GFP cell line (PRAME+HLA-A*02+) and RS4:11- FF-Luc.GFP cell line (PRAME+ 
HLA-A*02neg.ve)].  
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3.9. IFNγ, IL2, TNFα ELISA  
Supernatant from Effector/Target co-culture was collected at 24 hours to measure 
IFNy, IL2 and TNFα released by iC9-SLL TCR T or NT T cells. The supernatant was 
analyzed by ELISA assay (R&D System, USA), following the manufacturer’s 
instructions.  
3.10. Chromium-release assay 
The cytotoxic specificity of T cells was evaluated using a standard 4- hour 51Cr-
release assay. Target cells were incubated in medium alone or in 1% Triton X-100 
(Sigma-Aldrich, UK) to determine spontaneous and maximum 51Cr release, 
respectively. iC9-SLL TCR T cells or NT T cells were plated in triplicate on PRAME+ 
HLA-A*02+ target cells [DAOY, CEM- T2 or CEM-T2 SLL (loaded with SLL-PRAME 
peptide) cell line] or on PRAME+ HLA-A*02- target cells (RS4:11 and D283). In 
selected experiments, we used sorted CD8+ T cells transduced with iC9-SLL TCR as 
effector cells. After 6 hours of co-culture of effector and target cells, as described 
previously (106), the supernatant was collected and radioactivity measured with a 
gamma counter. The mean percentage of specific lysis of triplicate wells was 
calculated as follows: [(Experimental release-spontaneous release)/(maximal 
release-spontaneous release)]x100.  
3.11. RNA isolation and quantitative Real-Time PCR 
Total RNA was purified and reverse transcribed (Thermo Scientific, USA) as 
previously described.(19,20) Quantitative RT-PCR (qRT-PCR) was performed 
employing Viia7 Sequence Detection System (Thermo Scientific, USA), using best 
coverage TaqMan gene expression assays, specific for each mRNA analysed 
(PRAME, ßIII-tubulin S100A, GFAP, GAPDH, ß-ACTIN, and ß2-MICROGLOBULIN). 
Expression signature for MB sub-grouping was performed by qRT-PCR using 
TaqMan probes. TaqMan Low Density Array was custom-designed with TaqMan 
assays for genes of interest. Each amplification was performed in triplicate, and the 
average of the three threshold cycles was used to calculate the amount of transcripts 
(Thermo Scientific, USA). Transcript quantification was expressed in arbitrary units 
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(AU) as the ratio of the sample quantity to the mean values of control samples 
(PBMCs of 8 healthy donors). Relative gene expression was calculated using the 
2(2DCt) method, where DCt indicates the differences in the mean cycle threshold 
(Ct) (113) between selected genes and three endogenous gene controls (GAPDH, ß-
ACTIN, and ß2-MICROGLOBULIN; data were shown only with respect to ß-ACTIN 
normalization).  
3.12. Molecular detection of retroviral transduced T cells 
Total DNA was purified according to manufacturer indications (Qiagen, USA). 
Retroviral vector was amplified by using TaqMan probe/primers directed towards an 
invariant region of the plasmid located between LTR and the transgene iC9-SLL 
TCR. Vector copy numbers for cells were normalized with respect to the copy 
numbers of the housekeeping gene ß-Actin.  
3.13. Xenograft mouse model for in vivo studies 
All immunocompromised NSG (NOD scid gamma) mice (strain NOD.Cg-Prkdcscid 
Il2rgtm1Wjl/SzJ) were purchased from Charles River and maintained in the animal 
facility at Sapienza University (where orthotopic models using stereotaxic MB 
implantation in mouse brains were performed) or in Plaisant Castel Romano (where 
Intraperitoneal (i.p.) model for the bioluminescence monitoring of the tumour using 
IVIS Image System was performed) in Rome. All procedures were performed in 
accordance with the Guidelines for Animal Care and Use of the National Institutes of 
Health (Ethical committee for animal experimentation Prot. N 03/2013 for University 
of Rome Sapienza, and Prot. N 088/2016-PR for Plaisant Castel Romano, 
respectively). For the orthotopic in vivo model, adult female NSG mice were 
anesthetized by intraperitoneal injection of ketamine (10 mg/kg) and xylazine (100 
mg/kg). The posterior cranial region was shaved and placed in a stereotaxic head 
frame. DAOY cells were prepared from fresh culture to ensure optimal viability. MB 
cells (2 x105 per 5 µl) were stereotaxically implanted into the cerebellum at an 
infusion rate of 1 µl/min by using the following coordinates, according to the atlas of 
Franklin and Paxinos: 6.6 mm posterior to the bregma; 1 mm lateral to the midline; 
and 2 mm ventral from the surface of the skull. After injection, the cannula was kept 
in place for about 5 min for equilibration of pressures within the cranial vault. The skin 
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was closed over the cranioplastic assembly using metallic clips. Ten days following 
tumor implantation, the animals were randomly divided into three groups: Group 1 = 
intracranial injection of CTRL -T lymphocytes; Group 2: intracranial injection of 
PRAME-T lymphocytes; Group 3: no lymphocyte injection. In selected experiments, T 
cells were inoculated intravenous (i.v.) into the tail vein. On the same day of T-cell 
infusion, IL2 i.p. treatment was started (1.000 U/animal in PBS; administered twice a 
week). After 4 weeks, animals were sacrificed and brains were fixed in 4% 
formaldehyde in 0.1 M phosphate buffer (pH 7.2) and paraffin embedded. For brain 
tumor volume calculation, serial thick coronal sections (2 µm) starting from the 
mesencephalon to the end (HALF) of cerebellum were performed. In order to in vivo 
estimate tumor control within a setting of bulky tumor, we also carried out an i.p. 
model of MB. In particular, in NSG male mice of 5 weeks age, we engrafted i.p. 2x106 
PRAME+ tumor cells (DAOY-FF-Luc.GFP) re-suspended in Matrigel (Becton 
Dickinson, USA). Ten days later, when the light emission of the tumor was 
consistently measurable, mice received i.p. injection of 107 iC9-SLL TCR T cells or 
control, un-transduced T cells. Tumor growth was evaluated using IVIS imaging 
system (PerkinElmer, USA). Briefly, a constant region of interest was drawn over the 
tumor regions and the intensity of the signal measured as total photon/sec/cm2/sr 
(p/s/cm2/sr), as previously described.(24) For In vivo CID study, we genetically 
modified T cells (CNT and iC9-SLL TCR T cells)to express the Fire Fly luciferase and 
these cells monitored through IVIS technologies (DAOY cell line was wt and 
stereotaxically implanted). After 4 days, the drug AP1903 (100mg/mouse) was 
infused and mice analyzed for the iC9-SLL TCR T cells presence. 
 
3.14. Histological and immunohistochemistry data 
The histopathologic H&E analysis for the orthotopical models was performed on 40 
sections (2 µm each), sampled every 40 µm on the horizontal plan of the cerebellum, 
in which the cerebellum was identified and outlined at 2.5x magnification. Tumor area 
of every slice was evaluated with a microscope (Axio Imager M1 microscope; Leica 
Microsystems GmbH, Germany) equipped with motorized stage and Image Pro Plus 
6.2 software. The following formula was used to calculate the mouse brain tumor 
volume: tumor volume = sum of measured area for each slice x slice thickness x 
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sampling frequency. For immunohistochemistry (IHC) analysis, the sections were 
deparaffinized with xylene, sequentially rehydrated in ethanol, and incubated in 0.3% 
hydrogen peroxide for 10 minutes to quench endogenous peroxidase activity. 
Immunostaining was performed using the Vectastain Elite ABC kit (Vector 
Laboratories, Burlingame, CA). Nonspecific binding was blocked by incubation with 
normal rat serum for 30 minutes. The sections were then incubated with anti-CD3 
antibody (1:100, DAKO) or anti-PRAME (1:100, ABCAM) at 4°C for 60 minutes. 
Sections were incubated with a biotinylated secondary antibody (anti-mouse or anti-
rabbit IgG) for 30 minutes, washed, and incubated for another 30 minutes with ABC 
(avidin and biotinylated enzyme complex) reagent. Colourwas developed by adding 
peroxidase substrate diaminobenzidine. Sections were counterstained with Mayer's 
hematoxylin (Sigma-Aldrich) and, finally, mounting solution and coverslips were 
added.  
3.15. Mouse behavioural studies 
Mice were stereotaxically implanted with DAOY (0.2x106/mouse). Ten days after, 
CNT or iC9-SLL TCR T cells (1x107 cells/mouse) were inoculated i.v. into the tail 
vein. To evaluate the neurological effect of potential side effects due to T cell 
expansion, beginning on day before T cell infusion, throughout the period of tumor 
eradication (day 14), all the animals (n=8; 4 in ech cohort of treatment) were 
assessed using a modified Smith-Kline Beecham, Harwell, Imperial College, Royal 
London Hospital, phenotype assessment (SHIRPA) protocol (114). This 
comprehensive behavioural assessment involves a battery of 33 semi-quantitative 
tests for general health and sensory function, baseline behaviours and neurological 
reflexes. The procedures were carried out in an open testing environment away from 
the home cage, and took 15–20 min per animal daily.  
3.16. Statistical analysis 
All data are presented as means ± SD. Student t test was used to determine the 
statistical differences between samples, and p value <0.05 was considered to be 
statistically significant. Maximum likelihood method (115) using R2: Genomics 
Analysis and Visualization Platform (http://r2.amc.nl) was applied to calculate the 
expression level of 19.2x103 AU as cut-off to stratify patients based on PRAME 
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expression. The Kaplan-Meier method was used to estimate overall survival (OS) 
probabilities; differences between groups were compared with the log-rank test. 
Hazard ratio for death was calculated with 95% confidence interval (CI). No 
evaluable samples were excluded from the analyses. Animals were excluded only in 
the event of death after tumor implant, but before T-cell infusion. Neither 
randomization nor blinding was done during the in vivo study. However, mice were 
matched based on the tumor signal for control and treatment groups before infusion 
of control or gene-modified T cells in the i.p. bulky MB tumor model. In this last 
model, to evaluate tumor growth over time, bioluminescence signal intensity was 
collected in a blind fashion. Bioluminescence signal intensity was log transformed 
and then compared using a two-sample t-test. The analysis of the neuropathologist 
(F.G.), aimed at quantifying tumor volume, was performed in a blind fashion. We 
estimated the sample size considering the variation and average of the samples. We 
tried to reach a conclusion using a sample size as small as possible. We estimated 
the sample size to detect a difference in averages of 2 standard deviation at the 0.05 
level of significance with an 80% power. Graph generation and statistical analyses 
were performed using Prism version 6.0d software (GraphPad, USA).  
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4. Results 
4.1. PRAME expression in MB at diagnosis and relapse  
We evaluated CTAs gene expression data-sets	through bioinformatics analysis. The 
data evidenced that the majority of known CTAs are either downregulated or not 
modulated (figure 3A and B) in MB samples respect to normal cerebellum. Only 
CTAs PRAME (Figure 3C) and CT22 (a CT-antigen, also known as Sperm 
Autoantigenic Protein 17 - SPA17, with a wide expression in somatic tissues) have a 
different expression pattern. (116) Starting from these observations, we decided to 
focalize our attention on PRAME, analyzing its mRNA expression levels in 10 normal 
adult (NAHC) and 8 foetal cerebella (NFHC), underlining a less expression than 
mononuclear cells derived from 8 healthy donors (PBMC, Figure 4A). We then 
studied PRAME mRNA levels in tumor samples collected at diagnosis from 60 MB 
patients diagnosed/treated at OPBG. The clinical-pathological data of the considered 
MB patients are summarized in Table 1. The 82% (49 out of 60) of all tumor samples 
showed a significative higher PRAME expression (average 92,2x103±248x103; range, 
0.9x103-1500x103 AU) respect to NAHC tissues (average, 0.8x103 AU; p<0.0001), 
with no relevant differences among the four molecular subgroups (Figure 4A). 
Noteworthy, Kaplan–Meier analysis evidenced that high PRAME mRNA expression 
correlates significantly with a worse Overall Survival (OS) probability in the 51 
patients for which follow-up data were available in our Institution. This correlation 
remains statistically significant considering the PRAME mRNA expression cut-of as 
the maximum likelihood estimation threshold (117) of 19.2 X 103 AU (p=0.0004; 
Figure 4B), the median value of 7.705 X 103 AU (p=0.0003; Figure 4E), the first 
quartile value of 0.381 X 103 AU (p=0.002; Figure 4F) and third quartile value of 
36.221 X 103 AU (p=0.0006; Figure 4G) quartile. Indeed, the median overall survival 
was 29.1 months (95% CI, 6 to 62) in high-PRAME-expressing patients group versus 
59.4 months (95% CI, 6 to 158) in low-PRAME-expressing patients group (p=0.0004; 
Figure 2B. Hazard ratio for death, 4.258; 95% CI, 2.288 to 15.39; p=0.0031). 
Considering patients according to the four molecular subgroup, we verified a 
significant correlation between high PRAME expression and worse OS in SHH-MB 
(n=9; Figure 4C, p=0.0038) and G3-MB (n=19; Figure 4D, p=0.0075) subgroups; this 
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correlation was not statistically significant in WNT-MB (n=9) and G4-MB (n=14) due 
probably to the low number of patients studied. PRAME expression also correlated in 
our patient’s cohort with male gender (p=0.0279). We also analyzed PRAME 
expression in two MB patients (one case of SHH-MB and one of Group 3-MB) for 
which tumor biopsies were available both at diagnosis and at time of relapse, 
demonstrating high level of the antigen in recurrent MBs (Figure 5A). After all, IHC 
analysis shows rilevant PRAME protein expression in MB tumour samples, ranging 
from 20% to more than 90% of positivity in tumour cells, whereas the expression of 
PRAME protein were negligible in normal brain (Figure 5B).  
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Figure 3 
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Figure 3.A, CTA down modulated in MB respect normal cerebellum. CTA mRNA gene 
expression profiles across Gilbertson (GEO ID: GSE37418), Kool (GEO ID: 
GSE10327),Pfister (P=GEO ID:GSE49243; P2=ps_avgpres_mb500affym223_u133p2), 
Fattet/Delattre (GEO ID: GSE74195) datasets exploring CTA expression in either normal 
brain (N) or patients with MB. Numbers in the legend indicate the number of samples 
evaluated in each dataset. We have included in the analysis the following CTAs: MAGEA1 
(melanoma antigen family A1), NA88 – VENTX (VENT homeobox), GAGE1 (G Antigen 1), 
SSX1 (synovial sarcoma, X breakpoint 1), MAGEA4 (melanoma antigen family A4), CAGE1 
(cancer antigen 1), LUZP4 (leucine zipper protein 4), TPTE (Transmembrane phosphatase 
with tensin homology), MAGEC1 (melanoma antigen family C1) and MAGEA3-6 (melanoma 
antigen family A3/6). B, CTA not modulated in MB respect normal cerebellum. CTA 
mRNA gene expression profiles across Gilbertson (GEO ID: GSE37418), Kool (GEO ID: 
GSE10327), Pfister (P=GEO ID: GSE49243; P2=ps_avgpres_mb500affym223_u133p2), 
Fattet/Delattre (GEO ID: GSE74195) datasets exploring CTA expression in either normal 
brain (N) or patients with MB. Numbers in the legend indicate the number of samples 
evaluated in each dataset. We have included in the analysis the following CTAs: SLCO6A1  
(Solute carrier organic anion transporter family, member 6A1), FMR1NB (fragile X mental 
	
	 	
1 2 
30	
	
retardation 1 neighbor), HCA661 (transcription factor Dp family, member 3), OY-TES-1 
(ACRBP, acrosin binding protein), SYCP1 (synaptonemal complex protein 1), NY-ESO-1, 
FATE (fetal and adult testis expressed 1), SPANXA1/B1 (Sperm protein associated with the 
nucleus, X-linked, family member A1), MAGEB1 (melanoma antigen family B1GAGE1), 
BAGE (B melanoma antigen), SPANXB1 (family member B1). C, PRAME mRNA 
expression data from public datasets of expression profiles in MB patients. (1) PRAME 
mRNA gene expression profiles across Gilbertson (GEO ID: GSE37418), Kool (GEO ID: 
GSE10327), Kool/Pfister (GEO ID: GSE49243), Fattet/Delattre and de Bont (GEO ID: 
GSE74195) datasets exploring PRAME expression in either normal brain (black plot circles) 
or patients with MB (red plot circles). Numbers indicate the number of samples evaluated in 
each dataset. (2) PRAME mRNA gene expression profiles across Gilbertson, Kool and 
Pfister datasets, exploring PRAME expression in patients with different MB-subtypes. 
Numbers indicate the number of samples evaluated in each MB subtype. 
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Figure 4 
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Figure 4. PRAME mRNA expression and its correlation with clinical feature of MB.A, 
Relative expression of PRAME mRNA in PBMCs isolated from 8 healthy donors, 10 normal 
adult human cerebella (NAHC), 8 normal fetal human cerebella (NFHC), biopsies from 10 
patients with WNT-MB pathway subtype, 14 patients with SHH-MB pathway subtype, 20 
patients with Group 3-MB, and 16 patients with Group 4-MB. Transcripts quantification was 
expressed in AU versus the average expression of PRAME mRNA observed in PBMCs 
isolated from 8 healthy donors. *≤ P 0.05; **≤ P 0.001; ***≤ P 0.0001; ****≤ P 0.00001. B, 
Kaplan–Meier analysis for OS in all 51 patients with MB with a known follow-up (n=51), 
stratified by PRAME mRNA expression >19.2x103 AU or 19.2x103 AU, respectively. 
Differences between groups were compared with the log-rank test. C and D, Kaplan–Meier 
analysis for OS in patients with SHH-MB (C) and G3-MB (D) with more than 5 years of 
follow-up (n=51), stratified by PRAME mRNA expression >19.2x103 AU or 19.2=103 AU, 
respectively. E, F, G, Differential cut-off for PRAME mRNA expression and their 
correlation with clinical feature of MB. Kaplan-Meier analysis for overall survival (OS) in 
all 51 MB patients with a known FU (n=51), stratified by PRAME mRNA expression 
considering the cut-off of median value of 7.705 x 103 AU (E), 1° quartile value of 0.381 x 103 
AU (F) or 3° quartile value 36.221 x 103 AU (G), respectively. Differences between groups 
were compared with the log-rank test. 
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Figure 5. A, MB tissues from two patients in relapse show high level of PRAME 
expression. Relative expression of PRAME mRNA from matched primary-metastases MB 
tissues of patient with Group3-MB or with SHH-MB at diagnosis (dark gray bar) or at the time 
of relapse (light gray bars). PRAME mRNA expression in PBMC from 8 healthy donors has 
been added for comparison (black bars). B,Immunohistochemistry results of histological 
sections to evaluate PRAME expression. IHC images of PRAME staining of testis (positive 
control), normal cerebellum and three MB patients. Original magnification 10X and 20X . 
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4.2. Retroviral vector carrying iC9 and PRAME-SLL specific 
αβTCR allows stable and functional expression of the 
transgenes.  
TCR (α and β chains) sequences specific for PRAME-SLL in frame with iC9 
sequences (100), were cloned, codon-optimized, and encoded into a retroviral vector 
(iC9-SLL TCR, Figure 6A). Then, primary T cells or CD8+ sorted T cells (derived 
from PBMCs of healthy donors) were transduced with the generated retrovirus and 
expanded in the presence of cytokine IL2. About Six days after transduction, 
53%±8,6% of CD3+ T cells stained for TCRVβ1 (to which PRAME-SLL TCR β chain 
belongs) and 32%±7,8% of CD8+ T cells were detected positive for SLL dextramer 
(Figure 6B shows an explicative example, whereas the median level of transduction 
reached in 8 independent experiments is shown in Figure 6C). In particular, CD4+ T 
cells were also significantly transduced with iC9-SLL TCR, as shown by the 
expression of TCRVβ1; however, using SLL-dextramer staining, CD4+ cells resulted 
negative for the	SLL-TCR pairing, since SLL-dextramer staining is specific only for 
CD8+ cells (Figure 6B). Moreover, no significant differences in the transduction level 
(considering TCRVβ1 or dextramer staining analysis) were detectable between total 
T cells and CD8+ selected T cells.  
Starting from this observation, we decided to select through a SLL-dextramer 
microbeads, from the genetically modified T cells, the subset that express the correct 
SLL-TCR α and β chains pairing. Our in vitro data demonstrated that the selected 
SLL-TCR+ T cells stably expressed the transgene (Figure 6B) and were able to 
expand, generating a great number of iC9-SLL TCR T cells. Analyzing these 
genetically modified T cells, they showed a polyclonal phenotype after transduction, 
since no preferential TCRβ family usage has been observed in SLL-dextramer+ T 
cells, beside SLL-specific Vβ1 repertoire (Figure 6E). Furthermore, no proliferative 
differences were found between transduced T cells or non-transduced T cells (CNT T 
cells) when co-cultured with the pleiotropic cytokine IL2 (10,7±7,6 and 17.5±16,5 fold 
expansion at day 15, respectively, Figure 6D). The exogenous expressed SLL TCR 
was functional, since iC9-SLL TCR T cells produce IFN-γ in response to the CEM-T2 
cell line loaded with the SLL peptide (until 10-5 M concentration), but not with the 
irrelevant PRAME-peptide ALY (Figure 7A). In potency experiments, through Cr51 
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release assay, we demonstrated that SLL peptide-pulsed CEM-T2 cells were lysed 
by	 iC9-SLL TCR T cells at higher extent than un-loaded CEM-T2 (i.e. a HLA-A*02+ 
cell line characterized by low PRAME expression, as shown in Figure 5E; 
69,8%±6.5% vs 8.0%±1.8% specific lysis, respectively at the Effector:Target (E:T) 
ratio of 20:1,p≤0.005 Figure 7B). Noteworthy, iC9-SLL TCR T cells, when co-cultured 
with the tumor cell line U266 (HLA-A02+ PRAME+) in a ratio 1:1 (effector:target),	
were able to eliminate tumor cells without SLL-peptide pre-loading (Figure 7G). As 
previously mentioned, to improve in a clinical perspective the safety of our 
transduced T cells, we included in the retroviral vector the iC9-suicide gene. In order 
to verify the capability of iC9 to induce apoptosis in transduced cells we perform 
functional experiments. Results demonstrated that also the second transgene is 
active, since iC9-SLL TCR T cells were promptly eliminated upon 24-hour exposure 
to 20 nM AP1903 (Figure 7C). The residual CD3+ Vβ1+ cells (average, 6.3%±3.9%) 
still alive after 72 hours of AP1903 exposure were further expanded in culture with 
IL2, and tested for the presence of vector DNA, showing the absence of genetically 
modified T cells (Figure 7D).  
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Figure 6 
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Figure 6.Generation of iC9-SLL TCR T cells.A, α and β chains of SLL-PRAME TCR were 
cloned in frame with the suicide gene iC9 in a retroviral vector, with the separation of the 
transgenes through 2A sequences. B, Flow cytometry analyses in an esemplificative donor 
of untransduced (CNT T cells, top) or transduced with the retroviral vector iC9-SLL TCR 
(bottom) polyclonal T cells in vitro, activated through OKT3/CD28. TCR Vβ1 staining is 
shown in total CD3+, CD3+/CD4+, CD3+/CD8+ cells, whereas SLL-dextramer+ staining is 
shown in total CD3+ and in SLL-dextramer–sorted T cells (postsorting). C, The average of 
the positive TCR Vβ1 cells was shown in total CD3+, CD3+ CD8+, and CD3+ CD4+ T cells, 
whereas the average of positive SLL-dextramer cells was shown in CD3+ CD8+ and CD3+ 
CD4+ T cells. Data are expressed as average ± SD from 8 healthy donors at day 15 of in 
vitro expansion.D, Fold expansion of untransduced T cell (CNT, gray dashed line) and iC9-
SLL TCR T cell (black line), evaluated by Trypan blue count assay. Data represent results 
from 8 healthy donors. E, TCR-Vβ repertoire analysis in iC9-SLL TCR T cells. TCR-Vβ 
repertoire analysis showed no significant difference in TCR Vβ usage between control T cells 
(CNT) and the transduced iC9-SLL TCR T cells (positive for Vβ1) subdivided in the T cell 
subset positive or negative for SLL tetramer staining. 
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Figure 7. A-D, In vitro functional analysis of iC9-SLL TCR T cells. A, iC9-SLL TCR 
avidity assessed by IFNg ELISpot assays of CEM-T2 cell line loaded with an irrelevant 
peptide (gray bars) and the SLL-specific peptide (black bars). Ionomycin/phorbolmyristate 
acetate (I/PMA) was used as positive control. SFCs per 105 cells. Data represent the mean ± 
SD of triplicate experiments. B, In vitro51Cr release assay evaluating cytolytic activity of iC9-
SLL TCR T cells on CEM-T2 tumor cell line loaded with an irrelevant (irr; gray line) or SLL-
specific peptide (black line). C, Evaluation of percentage of alive (Annexin-V_/ 7AAD_) T cells 
grown in IL2 and exposed to 20 nmol/L AP1903 for 24, 48, or 72 hours. CD3+ TCR Vβ1+ T 
cells negative for Annexin-V/7AAD staining were considered to be alive after the activation of 
the iC9 suicide gene. Data from four healthy donors are expressed as average±  SD. D, 
Analysis of the presence of retroviral vector sequence in iC9-SLL TCR T cells residual after 
AP1903 exposition. Quantitative PCR targeting specific retroviral sequence was carried out 
to establish whether Vβ1+ T cells residual after AP1903 exposition were genetically modified. 
Data from three independent experiments show that Vb1þ residual cells did not carry iC9-
SLL TCR vector. E-J, PRAME expression in tumor cell lines and in vitro functional 
analysis of iC9-SLL TCR T cells towards neoplastic cell lines. E, Average of relative 
PRAME mRNA expression (AU) in 8 PBMC samples of adult healthy donors, MB cell lines 
DAOY (HLA-A*02+), D283 (HLA-A*02+, down-regulating HLA Class I molecule), Multiple 
Myeloma cell line U266 (HLA-A*02+),  Lymphoma cell line HDML2 (HLA-A*02-), leukemia 
cell line RS4;11 (HLA-A*02-), and lymphoblastoid cell line CEM-T2 (HLA-A*02-). F, HLA-
A*02 expression in D283 cell line untreated (light gray histogram) and after treatment with 
IFNγ (1000U/mL) for 48hrs (dark gray histogram). G, 7-days co-culture assay between 
effector cells [control CNT T cells (gray bars) or iC9-SLL TCR T cells (black bars)] and 
PRAME+ HLA-A*02+ multiple myeloma U266 or  PRAME+ HLA-A*02- leukemia RS4;11 cell 
lines (1:1 Effector:target ratio). Data are expressed as average ± SD from 3 donors. H, in 
vitro 51Cr release assay evaluating cytolytic activity of un-transduced (CNT) T cells (dotted 
line) and total CD3+ iC9-SLL TCR T cell (continuous line) vs DAOY cell line. I, in vitro 51Cr 
release assay evaluating cytolytic activity of CD8+ selected T cells un-transduced (CNT) 
(dotted line) or transduced with iC9-SLL TCR T cell (continuous line) vs HLA-A*02+ DAOY 
cell line. J, in vitro 51Cr release assay evaluating cytolytic activity of un-transduced (CNT) T 
cells (dotted line) and total CD3+ iC9-SLL TCR T cell (continuous line) vs HLA-A02- RS4;11 
cell line. n=3 replicates per point; representative of four donors. * p-value=<0.05, ** p-
value=<0.01, *** p-value=<0.001. 
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4.3. PRAME-specific TCR–redirected T cells exert antitumor 
activity toward HLA-A*02-matched MB cell line 
The cytotoxic activity of iC9-SLL TCR T cells was also verified, by using standard 6-
hour Cr51 release assays, against the HLA-A*02+ PRAME+ MB DAOY cell line and a 
negative control, namely the HLA-A*02neg.ve PRAME+ RS4;11 cell line (Figure 7). 
We evidenced the greater lysis of HLA-A*02+ PRAME+ MB cell line DAOY by iC9-
SLL TCR T cells (43.3%±17.7% specific lysis at the E:T ratio of 20:1) than that 
observed with CNT T cells (11.3%±6,1%; p=0.004; Figure 7H). Otherwise, we 
performed functional experiments where we demonstrated no significant differences 
in cytotoxic activity between iC9-SLL TCR bulk T cells (Figure 7H) or iC9-SLL TCR 
CD8+ T cells (40.4%±15% specific lysis at the E:T ratio of 20:1) (Figure 7I). In 
addition, both transduced and control T cells showed negligible activity against the 
control target HLA-A*02neg.ve PRAME+ RS4;11 cell line (Figure 7J), underling the 
iC9-SLL TCR T cells specificity against the target. In longer-term assays, in which we 
co-cultured control or iC9-SLL TCR T cells with HLA-A*02+ PRAME+ DAOY cells for 
7 days, we found a significant reduction of DAOY tumor cells in the presence of iC9-
SLL TCR T cells at E:T ratio of 1:1 (Figure 8A and 8B). To obtain similar results also 
on D283 cell line characterized by down-regulation of the HLA-A*02 molecule (Figure 
7F), we needed to pre-treat target cells with IFNγ for 48 hours (Figure 8A). The 
efficacy of iC9-SLL TCR T cells against MB cell lines was confirmed by IFN-γ 
production assessed by ELISA assays (Figure 8C). Moreover, we sought to evaluate 
whether SLL+ sorted T cells were still able to be functional towards HLA-A*02+ 
PRAME+ DAOY cells. In particular, tumor control was mediated by the CD8+ Vβ1+ T 
cell subpopulation, whereas neither antigen-specific proliferation (Figure 9A and 
Figure 9B and 9C), nor a direct anti-tumor activity (Figure 8B), as well as cytokine 
production, evaluated in terms of IFN-γ (Figure 9D), IL2 (Figure 9E) and TNF-a 
(Figure 9F), was observed when CD4+ Vβ1+ T cells were used as effector cells. In 
order to confirm our findings, we also decided to evaluate whether iC9-SLL TCR T 
cells were activated on primary HLA-A*02+ MB cells derived from MB patient (#1). 
These cells were in vitro expanded until passage 5 and were confirmed to maintain 
both high PRAME expression (Figure 9G) and other neuronal markers, including 
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B3TUBB, S100A and GFAP. We observed a significant increase in IFN-γ SFC T 
cells, when iC9-SLL TCR T cells were challenged with HLA-A*02+ MB #1 cells, 
irrespectively of pre-treatment with IFN-γ, with respect to the control condition (CNT T 
cells; p=0.004). Negligible activity was valuated when iC9-SLL TCR T cells were 
stimulated in the presence of PRAME+ HLA-A*02- MB #2 and #3 primary tumor cells 
(Figure 8D).  
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Figure 8 
 
 
 
Figure 8. Long-term in vitro functional analysis of iC9-SLL TCR T cells against MB cell 
lines and primary patient-derived tumor cells.A, Seven-day co-culture assay between 
effector cells [control CNT T cells (gray bars) or iC9-SLL TCR T cells (black bars)] and 
PRAME+ HLA-A*02+ MB cell line DAOY, PRAME+ MB cell line D283 down-regulating HLA 
Class I molecule, D283 cell line pretreated with IFNg (1,000 U/mL) for 48 hours, and 
PRAME+ HLA-A*02- RS4;11 cell line (1:1 E:T ratio). Data are expressed as average ± SD 
from three healthy donors. B, Seven-day co-culture assay (1:1 E:T ratio) between PRAME+ 
HLA-A*02+ MB cell line DAOY (black bars) or PRAME+ HLA-A*02- RS4;11 cell line (gray 
bars) and effector cells (control CNT T cells or Vb1þ iC9-SLL TCR T cells) sorted in the 
subset of CD3+, CD3+ CD4+, and CD3+ CD8+ T cells. Data are expressed as average ± SD 
from three healthy donors. C, IFNg quantification by ELISA assay of supernatant after 24 
hours of co-culture assay described in A and B. * p-value=<0.05, ** p-value=<0.01, *** p-
value=<0.001. D, IFNg ELISpot assays of un-transduced CNT T cells (gray bars) or iC9-
SLLþ TCR T cells (black bars) challenged with primary MB cells derived from patient with 
PRAME+ HLA-A*02+ (#1) with or w/out IFNg pretreatment, or patients with PRAME+ HLA-
A*02_ (#2 and #3). SFCs per 105 cells. Data represent the average ± SD of triplicate 
experiments (* p-value=<0.05, ** p-value=<0.01).  
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Figure 9. A, proliferation analysis of Vβ1+ CD4+ and Vβ1+ CD8+ T cells exposed to 
HLA-A*002+ PRAME+ cell line.  CD4+ and CD8+ CNT T cells or genetically modified with 
iC9-SLL TCRwere analyzed for basal proliferation level (upper panels), 5 days of coculture 
with HLA-A*002- PRAME+ cell line (RS4;11; middle panels) or HLA-A*002+ PRAME+ DAOY 
cell line (lower panels). CFSE dilution was applyed to visualize T cell proliferation. One 
representing donor is shown. B-F, Functional analysis of Vβ1+ CD4+ and Vβ1+ CD8+ T 
cells exposed to HLA-A*002+ PRAME+ MB cell line.  CD4+ (pointed color bars) and CD8+ 
(plain color bars) CNT T cells (gray bars) or genetically modified with iC9-SLL TCR (black 
bars)were analyzed for basal proliferation level, after coculture with HLA-A*002- PRAME+ 
RS4;11 cell line or HLA-A*002+ PRAME+ DAOY cell line (after three days in panel B, and 5 
days in panel C). CFSE dilution was applied to visualize T cell proliferation. Data represent 
results from 3 HDs. D-F, cytokine analysis was performed upon 24 hrs of effector T cells 
coltured alone (white bars) or stimulated to HLA-A*002+ PRAME+ DAOY cell line (black 
bars) or HLA-A*002- PRAME+ RS4;11 cell line (gray bars). CD8+ but not CD4+ genetically 
modified with iC9-SLL TCR produced significant amount of IFNγ (D), IL2 (E) and TNFα (F). 
G, Differential expression of PRAME mRNA between in vitro expanded primary cells (black 
bars) and the correspondent tumor biopsy (gray bar) of MB patient#1, #2 and #3. 
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4.4. iC9-SLL TCR T cells exert antitumor activity in vivo in 
xenogeneic mouse models of MB.  
To strength our in vitro data, we performed in vivo antitumor experiments using iC9-
SLL TCR+ T cells and xenogeneic NSG mouse models i.p. engrafted in Matrigel with 
a bulky MB tumor, represented by DAOY cells (2x106) genetically modified with firefly 
luciferase (FFLuc), to monitor tumor growth overtime by bioluminescent imaging (BLI) 
signal (Figure 10A). After establishment of bulky tumor (i.e. 20 days after DAOY i.p. 
injection), we treated	mice with either control (CNT) or iC9-SLL TCR T cells (Figure 
11A). On day 60 after T-cell infusion, 4 out of 5 mice treated with iC9-SLL TCR T 
cells had significantly better  tumor control than mice receiving CNT T cells 
(6.4×106±10×106 vs. 11300×106±8010×106 photons/second; respectively; p=0.03, 
Figure 11A and B). Then, in order to confirmed these  evidence also in orthotopic MB 
mouse model, DAOY cells (2x105) are stereotaxically implanted into the cerebellum 
(Figure 10B and 10C). After 10 days, the mice were divided in three subgroups and 
each one received further stereotaxic surgery to infuse placebo (namely, no T cells; 
n=3) or control T cells (namely, CNT T cells; n=6) or T cells genetically modified with 
iC9-SLL TCR (namely, iC9-SLL TCR T cells; n=6). On day +40, mice were sacrificed 
and cerebella surgically excised. By	histopathologic analysis we evidenced that mice 
receiving iC9-SLL TCR T cells	 showed significantly lower tumor cell mass as 
compared to controls (2/6 vs 6/6, respectively). Tumor volume analysis (calculated 
along serial histologic brain sections as previously described) (118) displayed a 
significant reduction of the mass formed by DAOY tumor cells in iC9-SLL TCR T 
cells-treated mice as compared to controls (Figures 11C and D). We were also able 
to observe a significant reduction of the tumor volume when iC9-SLL TCR T cells 
were administered by intra-venous (i.v.) infusion (Figures 12A and B). To 
demonstrate that tumor control is a direct consequence of the T-cell migration across 
the blood brain barrier (BBB), we sacrificed mice and carried out anti-human CD3 
IHC analysis on murine brain slides. Human T cells co-localized together with MB 
cells, while a negligible human T-cell infiltrate was seen in mouse brain sites not 
involved by the tumor (Figure 12C).  
Since, pseudoprogression phenomena could represent a side effect in our system, 
we have studied the kinetics of tumor elimination when MB cell line (marked with FF-
Luc) was intracranial implanted and T cells were injected i.v. In Figure 12D we 
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showed how tumor eradication was obtained in 15 days from T-cell infusion in the 
cohort of mice receiving iC9-SLL TCR T cells, this translating into a significant 
improvement of mice OS (Figure 12E). No neurological signs of toxicity was also 
recorded after iC9-SLL TCR T cell infusion, by applying comprehensive behavioural 
assessment involving a battery of 33 semi-quantitative tests for general health and 
sensory function, baseline behaviours and neurological reflexes.(114, 119) 
To validate the IC9 safety system also in T cells infiltrating the cerebellum, we 
genetically modified iC9-SLL TCR T cells with a retroviral vector carrying the FireFly 
Luciferase to follow their in vivo elimination upon the i.p. administration of AP1903. 
As shown by Figure 6F, the systemic administration of the dimerizing drug allows a 
significant reduction of the BLI in the mouse cohort receiving iC9-SLL TCR T cells, 
but not in mice infused with CNT T cells. Moreover, anti-hCD3 IHC analysis on 
cerebella slides of mice treated with iC9-SLL TCR T cells shows that the 
administration of AP1903 completely eliminates tumor T-cell infiltration (Figure 10G).  
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Figure 10 
 
Figure 10. Experimental plans of orthotopic xenograft mouse model for in vivo 
studies. A, To measuring tumour control within a setting of bulky tumour, we performed in 
vivo i.p. model of MB. In particular, in NSG male mice of 5 weeks age, we engrafted  i.p. 
2x106  PRAME+ tumor cells (DAOY-FF-Luc.GFP) re-suspended in Matrigel. Ten days later, 
the mice received i.p. injection of 107 iC9-SLL TCR T cells or NT T cells. Tumor growth was 
evaluated weekly using IVIS imaging system until day of the sacrifice (Xenogen). B, DAOY 
cells (2 x105 per 5 µl) were stereotaxically implanted into the cerebellum of adult 
anesthetized female NSG mice. After 10 days following tumour implantation, the animals 
were stereotaxically infused (at the same co-ordinates of tumor implant) with placebo (PBS), 
un-transduced or iC9-SLL TCR T cells. After 4 weeks, animals were sacrificed and brains 
were evaluated for histopathologic H&E analysis to calculate tumor volume. C, T cells were 
inoculated i.v. into the tail vein of mice stereotaxically implanted with DAOY-FF-Luc.GFP. 
Mice were monitored with IVIS imaging system until tumor eradication, and then monitored 
for OS and toxicity signs. 
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Figure 11 
 
 
 
 
 
 
 
Figure 11. iC9-SLL TCR T cells have in vivo antitumor activity against DAOY cell line. 
A and B, Intraperitoneal administration of 2x106 DAOY-FFluc cells into NSG mice (n=10), 
followed by T-cell infusions [107; 5 mice with untransduced (CNT) and 5 mice with iC9-SLL 
TCR T cells] and weekly BLI. BLI in individual mice from both treatment groups at day +49 
from T-cell infusion is shown in B. Scale, 1x106 to 1x108 photons/second/cm2/sr. C and D, 
Stereotaxical administration of 2x105 DAOY cells into NSG mice (n=15), followed by 
intratumor infusions of placebo (PBS, No T cells; n=3), untransduced (CNT; n=6; 107) or iC9-
SLL TCR T cells (n=6; 107). After 4 weeks, animals were sacrificed and brains were 
evaluated for histopathologic H&E analysis by serial section of the cerebellum. Tumor area 
(marked by asterisk where observed) of every slice was evaluated with a microscope,  and 
average ± SD of tumor volumes is shown in C, whereas exemplificative slide section 
(magnification, x4 ) of the cerebella is shown in D(* p-value=<0.05, ** p-value=<0.01). 
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Figure 12 
 
 
 
 
 
 
 
Figure 12. iC9-SLL TCR T cells infused systemically have in vivo antitumor activity 
against orthotopic DAOY cell line implant. A–C, Mice stereotaxically implanted with 
DAOY were infused intravenously (n=8) into the tail vein with untransduced (CNT; n=4; 107) 
or iC9-SLL TCR T cells (n=4; 107). Tumor area (marked by asterisk where observed) of 
every slice was evaluated with a microscope, and average ± SD of tumor volumes is shown 
in A, whereas exemplificative slide section (magnification, x4) of the cerebella is shown in B. 
C, Tumor T-cell infiltrates were analyzed by anti-hCD3 IHC on cerebella slides of mice 
sacrificed after 5 days from T-cell intravenous infusion. D and E, the dynamics of tumor 
regression after tail vein injection of untransduced (CNT; n=9; 107) or iC9-SLL TCR T cells 
(n=9; 107) was also evaluated, applying BLI in the orthotopic mouse model implanted with 
DAOY cell line genetically modified with FF-luc vector (n=18) (D). E, After the tumor 
clearance (by 14 days after iC9-SLL TCR T-cell infusion), mice were evaluated for OS until 
day 45 (end of the experiment). F and G, Mice stereotaxically implanted with WT DAOY 
were infused intravenously (n=8) into the tail vein control (CNT; n=4; 107) or dextramer-
sorted iC9-SLL TCR T cells (n=4; 107) also genetically modified with FF-Luc vector. At day 
+4 after T-cell infusion, all the mice were evaluated for BLI (black bars), and two mice in each 
cohort received intraperitoneal administration of 100 mg/mouse of the dimerizing AP1903 for 
two consecutive days. After additional 24 hours, all the mice were reevaluated for BLI (gray 
bars) and thereafter sacrificed. G, Tumor T-cell infiltrates were analyzed by anti-hCD3 IHC 
on cerebella slides of mice treated with iC9-SLL TCR T cells in the absence (top) or treated 
with AP1903 (bottom). The use of a systemically administration of AP1903 corresponded to a 
significant reduction of tumor T-cell infiltration.  
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5. Discussion 
 
 
MB is the most common, highly aggressive, central nervous tumor of childhood and 
we have to improve the nowadays clinical protocols to obtain a better outcome for 
patients. MB is a solid tumor located in cerebellum and the development of new 
approaches is a big challenge for researchers. This study shows that adoptive 
immunotherapy with T cells redirected toward PRAME antigen could represent an 
innovative therapeutic tool for this neoplasm. CTAs such as PRAME could be a 
promising target for immunotherapy, those are normally not expressed in normal 
tissues (except the testis, which, however, has no expression of human leukocyte 
antigen molecules). (120) Several authors reported PRAME expression in many 
cancers, but the biological functions of PRAME expression in cancer is not yet 
completely elucidated due to the controversial association between PRAME 
expression and disease prognosis. (121-123) In particular, in solid malignancies, 
including head and neck cancer, (124,125) liposarcoma, (126) uveal melanoma, 
(127) osteosarcoma, (128,129) breast cancer (130) and neuroblastoma (131) high 
PRAME expression correlates with advanced stage disease and poor clinical 
outcome, whereas in pediatric acute leukemia PRAME overexpression was found to 
predict good outcome. (132,133) The expression of PRAME in MB has been 
previously evaluated and reported in gene expression datasets and publications 
(104,105) as having no correlation with patient clinical outcome. (105) We evaluated 
PRAME antigen	 expression levels in patients with MB and 82% of samples had 
PRAME mRNA expression levels higher than those of normal adult cerebellum. By 
applying a maximum-likelihood analysis statistical tool, we defined a PRAME 
expression cut-off able to subdivide patients into two categories, namely high (19 out 
of 51; 37%) and low PRAME- expressing patients. A low expression of PRAME 
correlated with a better 5-year OS probability, a finding similar to that observed in 
other cancers. (124,127,130,131) However, the correlation between better OS and 
low PRAME expression was evidenced in patients belonging to SHH- and G3-MB 
subgroups, while for WNT- and G4-MB subgroups this findings have to be confirmed 
extending patients’ number. The statistically significant correlation between low 
PRAME expression and better OS probability was also maintained considering as 
cut-off for PRAME mRNA expression median value, as well as 1° and 3° quartiles.  
Due to the high PRAME expression in most patients with MB and the protein 
presence in relapse samples, we can consider this CTA as a promising candidate for 
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targeted immunotherapies. Indeed, PRAME has already been evaluated, both in vitro 
(106,108) and in vivo, for its immunogenicity. It has been reported that PRAME 
induces CTL-mediated immune responses in melanoma and in acute/chronic 
leukemia, (134) and, thus, represents a promising target for TAA-specific immune 
therapies. Several vaccination trials have been recently exploited with this CTA as 
immunotarget, using full-length protein/peptides either alone or in combination with a 
different tumor antigen. In particular, PRAME-based immunotherapy had an 
acceptable safety profile and induced anti-PRAME-specific humoral and cellular 
immune responses in melanoma, (135,136) as well as in non-small cell lung cancer, 
(137) prostate carcinoma and renal clear cell carcinoma. (136)  
However, data obtained by using PRAME as target in vaccination approaches, 
clearly evidenced the difficulty of in vivo reactivating PRAME-specific CD8+ T cells, 
even after several consecutive rounds of administration of the immunogenic 
protein/peptides. Starting from this observation, we decided to validate PRAME 
relevance as target for adoptive TCR T-cell therapy with an alternative approach. 
Indeed, we genetically modified	 T cells in order to express a high-affinity TCR, 
specific for the PRAME-derived peptide SLL. This peptide is presented in the context 
of HLA-A*02, which has a high worldwide frequency (i.e., 48.4% and 22.6% on 
average for Caucasian and Black ethnic groups, respectively). (138) Specifically, 
PRAME-specific TCR derived from the allogeneic HLA repertoire, was selected in 
view of its high avidity for the cognate peptide, high reactivity against several HLA-
A*02 positive PRAME-expressing tumor cell lines, as well as freshly isolated 
metastatic melanoma and primary leukemia cells. Anyway, genetically modified T 
cells were challenged against a large panel of non-malignant cells	and no reactivity 
was reported, including either fresh or activated B cells, T cells, MØ1 and MØ2 
macrophages, CD34 cells, immature dendritic cells (DCs) derived from either CD34+ 
or CD14+ cells. The T-cell clone from which SLL-TCR was derived exerted limited 
on-target reactivity against kidney epithelial cells and mature DC (mDC). However, 
the reactivity against the latter may be beneficial, since professional APCs like mDCs 
may contribute to enhance anti-tumor response and persistence of the infused T 
cells. (100) In the presented work, we chose to analyze the antitumor activity of 
PRAME-specific allo-TCR against MB cells. To increase the	 clinical safety of our 
modified PRAME-TCR product, the iC9 safety switch was introduced. In particular, 
iC9-SLL TCR T cells will be evaluated in an ongoing Phase I trial recruiting patients 
with either relapsed or refractory myeloid neoplasms (ClinicalTrials.gov Identifier 
NCT02743611).  
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Nowadays, iC9 is one of the most promising suicide genes for several reasons, 
including limited immunogenicity (139) and prompt activity, since more than 99% iC9-
expressing T cells (iC9-T cells) are eliminated both in vitro and in vivo within 2 hours 
from the administration of a single dose of the prodrug AP1903 (Rimiducid, a 
synthetic and non-toxic ligand leading to iC9 dimerization and triggering of the 
apoptotic pathway). (139,140) Indeed, iC9 activation alone has been shown to 
produce rapid and sustained control of graft-versus-host disease caused by donor-
derived iC9-T cells in recipients of allogeneic stem cell transplantation. (139-142) 
To the best of our knowledge, data that shows the	AP1903 possibility to reach the 
brain compartment and specifically eliminate genetically modified T cells through iC9 
suicide gene induction doesn’t exist. In this study, we have proved that the systemic 
administration of the dimerizing drug AP1903 in a MB orthotopic mouse model led to 
both BLI reduction in the total mouse body, including brain, and the lack of hCD3+ T 
cells in mouse cerebellum.  
With the performed experiments, we actually proved that both transgenes in the 
construct (namely, SLL-TCR and iC9) are functionally active and iC9-SLL TCR T 
cells. Notably, the CD8+ T-cell subset, evidence a huge cytotoxic activity against 
DAOY cells, as well as D283 cells in which we re-established HLA expression by 
IFN-γ treatment. IFNs have been used clinically to treat a variety of malignancies, 
protecting against disease by direct effects on target cells and by activating immune 
responses. (143,144) Our results support the possibility to use IFNs to trigger an 
adoptive T-cell therapy based on HLA-mediated target recognition. Fundamental for 
future prospective, despite the relevant difficulty to collect tumor material from 
patients with MB, we were able to challenge iC9-SLL TCR+ T cells with primary MB 
cells derived from the biopsy of one patient whose tumor cells were HLA-A*02+ and 
PRAME+, and two patients characterized HLA-A*02neg.ve and PRAME+ tumor cells, 
validating a significant PRAME specific T cell activation only in HLA-A*02+ patient. A 
larger cohort of primary MB tissues need to be evaluated to strength this data.  
The in vitro observations	were also confirmed by In vivo animal models, evidencing 
that adoptive TCR T-cell therapy could be a new useful immunotherapy strategy to 
target MB cells. Notably, the in vivo experiments were performed without IFNγ 
administration to obtain HLA upregulation. Moreover, a significant tumor control in 
the absence of undue toxicity was documented when both DAOY cells and iC9-SLL 
TCR T cells were injected through a stereotaxic approach in the mouse cerebellum. 
T cells were administered by i.v. infusion and demonstrated tumor control, coupled 
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with great T-cell infiltration of the tumour tissue and improved OS. No neurological 
sign of sufferance in the treated orthotropic mice was observed, proving that iC9-SLL 
TCR T cell activity was not associated to any side effect. These findings provide 
experimental support to the hypothesis that systemic administration of iC9-SLL TCR 
T cells could be a suitable and safe approach, particularly in view of T-cell migration 
across the BBB.  
In conclusion, our work shows that iC9-SLL TCR T cells selectively kill MB cells, and 
might represent an innovative, effective strategy leading to a significant improvement 
of the outcome of MB patients. This novel form of immunotherapy should be tested in 
early phase clinical trials for MB patients with either relapsed or newly diagnosed 
disease, but with features predicting a high risk of treatment failure.  
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